New molecular insights into osteosarcoma targeted therapy

被引:275
|
作者
Yang, Jilong [1 ]
Zhang, Wei [2 ]
机构
[1] Tianjin Med Univ Canc Hosp & Inst, Dept Bone & Soft Tissue Tumors, Tianjin 300060, Peoples R China
[2] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
genetic aberration; microRNA; molecular target; osteosarcoma; pathogenesis; TUMOR-GROWTH; GENE-EXPRESSION; CELL-LINES; IN-VITRO; PATHWAY; METASTASIS; OVEREXPRESSION; APOPTOSIS; PROTEIN; CANCER;
D O I
10.1097/CCO.0b013e3283622c1b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewRecent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets.Recent findingsThe genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-/, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-B ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets.SummaryThese translational studies in osteosarcoma have identified new molecular targets for osteosarcoma.
引用
收藏
页码:398 / 406
页数:9
相关论文
共 50 条
  • [21] Molecular mechanisms and microRNAs in osteosarcoma pathogenesis
    Kushlinskii, N. E.
    Fridman, M. V.
    Braga, E. A.
    BIOCHEMISTRY-MOSCOW, 2016, 81 (04) : 315 - 328
  • [22] Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy
    Huang, Xin
    Wu, Wei
    Jing, Doudou
    Yang, Lingkai
    Guo, Haoyu
    Wang, Lutong
    Zhang, Weiyue
    Pu, Feifei
    Shao, Zengwu
    JOURNAL OF CONTROLLED RELEASE, 2022, 343 : 107 - 117
  • [23] Molecular and Cellular Mechanisms of Melatonin in Osteosarcoma
    Lu, Ko-Hsiu
    Lin, Renn-Chia
    Yang, Jia-Sin
    Yang, Wei-En
    Reiter, Russel J.
    Yang, Shun-Fa
    CELLS, 2019, 8 (12)
  • [24] Autophagy regulation by microRNAs: Novel insights into osteosarcoma therapy
    Jamali, Zeinab
    Taheri-Anganeh, Mortaza
    Shabaninejad, Zahra
    Keshavarzi, Abdolkhalegh
    Taghizadeh, Hajar
    Razavi, Zahra Sadat
    Mottaghi, Reza
    Abolhassan, Mohammadreza
    Movahedpour, Ahmad
    Mirzaei, Hamed
    IUBMB LIFE, 2020, 72 (07) : 1306 - 1321
  • [25] Osteopontin as a biomarker for osteosarcoma therapy and prognosis
    Han, Xingwen
    Wang, Wenji
    He, Jingjing
    Jiang, Lei
    Li, Xun
    ONCOLOGY LETTERS, 2019, 17 (03) : 2592 - 2598
  • [26] Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma
    Yang, Ji-Long
    CHINESE JOURNAL OF CANCER, 2014, 33 (12) : 575 - 580
  • [27] New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
    Tan, D. S. P.
    Miller, R. E.
    Kaye, S. B.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1553 - 1559
  • [28] Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
    Gueron, G.
    De Siervi, A.
    Vazquez, E.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (11) : 1867 - 1880
  • [29] New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
    Akbari, Vajihe
    Chou, C. Perry
    Abedi, Daryoush
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (02):
  • [30] Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies
    Pereira-Silva, Miguel
    Alvarez-Lorenzo, Carmen
    Concheiro, Angel
    Santos, Ana Claudia
    Veiga, Francisco
    Figueiras, Ana
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2020, 148 : 88 - 106